Nurix Therapeutics, Inc. (NRIX)

NASDAQ: NRIX · IEX Real-Time Price · USD

16.59

+1.19 (7.73%)

At close: May 17, 2024, 4:00 PM

16.84

+0.25 (1.51%)

After-hours: May 17, 2024, 6:10 PM EDT

Nurix Therapeutics Income Statement

Financials in millions USD. Fiscal year is December - November.

Millions USD. Fiscal year is Dec - Nov.

Year	2023	2022	2021	2020	2019	2018
Revenue	76.99	38.63	29.75	17.82	31.12	0
Revenue Growth (YoY)	99.31%	29.84%	66.95%	-42.73%	-	-
Gross Profit	76.99	38.63	29.75	17.82	31.12	0
Selling, General & Admin	42.9	38	31.2	16.31	8.33	6.67
Research & Development	189.15	184.5	116.43	66.49	45.03	40.51
Operating Expenses	232.05	222.49	147.64	82.8	53.35	47.19
Operating Income	-155.06	-183.87	-117.89	-64.98	-22.24	-47.19
Other Expense / Income	-11.12	-3.51	-0.82	-1.21	-0.78	-38.27
Pretax Income	-143.95	-180.36	-117.06	-63.78	-21.46	-8.92
Income Tax	0	0	0.13	-20.54	0.24	0.51
Net Income	-143.95	-180.36	-117.19	-43.24	-21.7	-9.43
Shares Outstanding (Basic)	54	49	43	16	3	3
Shares Outstanding (Diluted)	54	49	43	16	3	3
Shares Change	11.79%	13.32%	173.68%	376.03%	16.87%	-
EPS (Basic)	-2.65	-3.71	-2.73	-2.76	-6.59	-3.35
EPS (Diluted)	-2.65	-3.71	-2.73	-2.76	-6.59	-3.35
Free Cash Flow	-89.77	-172.05	-90.03	-4.63	-1.05	-
Free Cash Flow Per Share	-1.65	-3.54	-2.10	-0.30	-0.32	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	-
Operating Margin	-201.41%	-476.01%	-396.26%	-364.66%	-71.46%	-
Profit Margin	-186.98%	-466.93%	-393.93%	-242.66%	-69.74%	-
Free Cash Flow Margin	-116.60%	-445.42%	-302.61%	-26.00%	-3.37%	-
EBITDA	-130.29	-169.55	-110.98	-61.6	-19.11	-
EBITDA Margin	-169.24%	-438.95%	-373.05%	-345.66%	-61.40%	-
Depreciation & Amortization	13.65	10.81	6.08	2.18	2.35	-
EBIT	-143.95	-180.36	-117.06	-63.78	-21.46	-8.92
EBIT Margin	-186.98%	-466.93%	-393.49%	-357.90%	-68.97%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).